Comparison of Peripheral Neuropathy Between the Original and a Generic Bortezomib in Multiple Myeloma Patients

Bortezomib has been the backbone of multiple myeloma treatment for more than 10 years, but its use in Brazil is very limited because of cost and reimbursement issues. The availability of generic bortezomib may increase the access of patients but the safety issues concern Brazilian health care professionals and patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Pedro Ivo Da Silva, Ana Carolina Figueiredo Modesto, Tatyana Xavier Almeida Matteucci Ferreira, Renato Sampaio Tavares, Danielle Le ão Cordeiro de Farias Source Type: research